background
rna
interfer
endogen
cellular
mechan
short
interf
rna
sirna
direct
sequenc
specif
degrad
target
mrna
sirna
synthes
chemic
modif
increas
stabil
reduc
doublestrand
rnainduc
immun
respons
without
affect
abil
elicit
degrad
target
mrna
object
studi
examin
use
chemic
modifi
sirna
mous
model
allergeninduc
airway
hyperrespons
method
chemic
modifi
sirna
design
screen
cellbas
report
assay
potent
sirna
screen
bone
marrowderiv
mast
cell
demonstr
efficaci
primari
cell
result
candid
sirna
formul
administ
sensit
mice
airway
challeng
allergen
administr
sirna
shown
reduc
airway
resist
significantli
sensit
challeng
mice
wherea
control
sirna
effect
conclus
data
demonstr
effect
introduc
target
sirna
prevent
induct
allergeninduc
airway
dysfunct
suggest
potenti
therapeut
applic
j
allergi
clin
immunol
abbrevi
use
ahr
airway
hyperrespons
bal
bronchoalveolar
lavag
bmmc
bone
marrowderiv
mast
cell
dsrna
doublestrand
rna
gfp
green
fluoresc
protein
hematoxylineosin
mch
methacholin
ova
ovalbumin
pa
period
acidschiff
rl
lung
resist
sirna
short
interf
rna
fig
lack
effect
sirna
airway
inflamm
sensit
challeng
mice
tissu
obtain
mice
challeng
sensit
challeng
antigen
b
sensit
challeng
expos
either
control
sirna
target
gfp
c
sirna
accord
protocol
outlin
fig
section
stain
pa
counterstain
identifi
mucuscontain
cell
inflammatori
cell
infiltr
asthma
heterogen
respiratori
diseas
character
airway
inflamm
airway
hyperrespons
ahr
revers
obstruct
despit
introduct
modif
new
establish
asthma
treatment
includ
inhal
corticosteroid
leukotrien
modifi
antiig
signific
proport
patient
requir
addit
therapi
result
remain
continu
need
addit
compound
may
function
novel
mechan
mous
model
allerg
airway
inflamm
ahr
develop
character
potenti
cellular
molecular
mediat
contribut
establish
mainten
inflammatori
hyperrespons
state
although
model
complet
mimic
human
diseas
state
provid
mean
test
potenti
benefit
target
diseas
mediat
explor
new
therapeut
technolog
rna
interfer
cellular
mechan
short
interf
rna
sirna
elicit
sequenc
specif
degrad
complementari
mrna
target
chemic
synthes
sirna
design
target
gene
interest
lead
reduct
target
mrna
nearli
undetect
level
sever
studi
demonstr
effect
synthet
sirna
halt
progress
respiratori
virus
includ
influenza
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
sar
limit
number
studi
demonstr
effect
synthet
sirna
nonvir
condit
includ
ischemia
reperfus
injuri
bleomycininduc
pulmonari
fibrosi
use
sirna
treatment
allergeninduc
ahr
previous
report
chemic
modifi
sirna
sever
advantag
unmodifi
counterpart
chemic
modif
use
stabil
sirna
serum
nucleas
improv
durat
effect
reduc
offtarget
effect
moreov
recent
public
demonstr
chemic
modifi
sirna
use
avoid
dsrnainduc
immun
respons
associ
unmodifi
sirna
sequenc
abil
certain
unmodifi
sirna
elicit
product
inflammatori
mediat
includ
ifng
tnfa
particular
concern
respiratori
immunolog
studi
mani
possibl
endpoint
sensit
releas
cytokin
sever
studi
shown
introduct
chemic
modif
abolish
dsrnainduc
cytokin
product
recent
report
demonstr
possibl
identifi
potent
sirna
bear
modif
nearli
nucleotid
modifi
sirna
elicit
dsrnainduc
immun
respons
wherea
unmodifi
sirna
sequenc
induc
product
ifng
tnfa
pleiotrop
cytokin
associ
sever
aspect
inflamm
ahr
key
role
airway
inflamm
ahr
illustr
experi
mice
treat
recombin
develop
eosinophilia
mucu
hypersecret
ahr
contrast
interfer
genet
elimin
prevent
develop
ahr
eosinophil
inflamm
act
sever
mechan
proinflammatori
role
mediat
induct
vascular
cell
adhes
numer
chemokin
eotaxin
macrophag
inflammatori
thymu
activationregul
chemokin
monocyt
chemoattract
protein
serv
recruit
activ
inflammatori
cell
howev
effect
appear
independ
inflammatori
cell
recruit
sever
studi
suggest
induc
ahr
absenc
inflammatori
cell
potenti
direct
effect
airway
smooth
muscl
addit
airway
inflamm
involv
mucu
secret
airway
epithelium
also
implic
subepitheli
fibrosi
therefor
may
play
role
airway
remodel
chronic
asthma
current
studi
examin
consequ
administ
stabil
sirna
sensit
challeng
mice
show
effect
approach
prevent
develop
allergeninduc
ahr
sirna
synthes
sirna
therapeut
boulder
colo
use
standard
synthesi
techniqu
duplex
sirna
prepar
mix
complementari
strand
equimolar
concentr
buffer
contain
mmoll
hepe
ph
mmoll
potassium
acet
mmoll
magnesium
acet
sequenc
sirna
use
vivo
shown
fig
two
chemic
modifi
control
sirna
also
use
studi
sirna
target
hepat
b
viru
use
control
vitro
studi
sens
strand
ib
gcacuucgcuucaccucugttib
antisens
strand
cagaggugaagcgaagugctt
modif
defin
fig
control
sirna
target
enhanc
green
fluoresc
protein
use
vivo
studi
sens
strand
ib
agaacggcaucaaggugaattib
antisens
strand
uucaccuugaugccguucutt
sirna
anneal
steril
dextros
formul
vivo
jetpei
qbiogen
irvin
calif
np
ratio
number
nitrogen
residu
jetpei
per
rna
phosphat
accord
manufactur
instruct
sirna
formul
immedi
inject
rat
sequenc
chemic
synthes
integr
dna
technolog
coralvil
iowa
xhoi
pmei
site
end
respect
sequenc
clone
site
report
plasmid
promega
madison
wi
creat
dual
luciferas
report
plasmid
target
interest
untransl
region
renilla
luciferas
luciferasereport
assay
perform
black
plate
fifteen
thousand
hela
cell
atcc
manassa
va
plate
ml
iscov
modifi
dulbecco
medium
life
technolog
grand
island
ny
supplement
bc
plate
incub
overnight
co
transfect
well
receiv
ml
mixtur
contain
ml
lipofectamin
ng
report
plasmid
sirna
dilut
optimem
invitrogen
carlsbad
calif
mixtur
incub
room
temperatur
minut
addit
cell
cell
incub
hour
transfect
renilla
firefli
luciferas
activ
determin
use
dual
glo
luciferas
reagent
promega
madison
wi
accord
manufactur
instruct
ratio
renilla
firefli
luciferas
activ
normal
observ
report
plasmid
transfect
control
sirna
stabil
motif
transfect
perform
triplic
data
report
mean
sd
pathogenfre
femal
balbcbyj
mice
week
old
obtain
jackson
laboratori
bar
harbor
maintain
ovalbumin
ova
free
diet
experiment
anim
use
studi
protocol
approv
institut
anim
care
use
committe
nation
jewish
medic
research
center
sensit
ova
conduct
intraperiton
inject
mg
ova
grade
v
sigmaaldrich
st
loui
mo
emulsifi
mg
alum
hydroxid
alumimuject
pierc
rockford
ill
total
volum
ml
conduct
day
apart
two
week
last
ova
sensit
aerosol
challeng
conduct
minut
consecut
day
day
ova
pb
use
ultrason
nebul
aeroson
ultrason
nebul
devilbiss
sommerset
pa
control
mice
receiv
aerosol
ova
challeng
day
airway
function
measur
describ
follow
collect
bronchoalveolar
lavag
bal
fluid
analys
sirna
treatment
mice
inject
intraven
via
tail
vein
mg
sirna
complex
vivo
jetpei
qbiogen
irvin
calif
volum
ml
hour
first
nebul
ova
challeng
day
hour
challeng
day
treatment
group
includ
anim
airway
function
assess
previous
describ
measur
chang
lung
resist
rl
respons
increas
dose
inhal
methacholin
mch
data
express
percentag
chang
baselin
rl
valu
obtain
inhal
pb
percent
chang
anim
group
n
present
mean
sem
immedi
assess
ahr
lung
lavag
via
tracheal
tube
pb
mlmous
cell
bal
fluid
pellet
supernat
determin
cytokin
level
frozen
total
leukocyt
number
determin
use
coulter
counter
coulter
corpor
hialeah
fla
cell
immobil
use
cytospin
shandon
ltd
runcorn
unit
kingdom
stain
leukostat
fisher
diagnost
pittsburgh
pa
differenti
cell
popul
determin
count
least
cell
lung
harvest
isol
bal
fluid
stain
previous
describ
briefli
lung
fix
inflat
ml
formalin
via
tracheal
tube
immers
formalin
section
tissu
prepar
stain
morpholog
core
facil
individu
section
stain
use
hematoxylineosin
character
inflammatori
cell
infiltr
period
acidschiff
pa
counter
stain
identifi
mucuscontain
cell
mast
cell
deriv
femur
bone
marrow
femal
balbcbyj
mice
jackson
laboratori
previous
describ
bone
marrow
cultur
iscov
modifi
dulbecco
medium
supplement
fb
summit
biotechnolog
fort
collin
colo
mmoll
life
technolog
mmoll
glutamin
mgml
streptomycin
uml
penicillin
condit
medium
kit
ligandcondit
medium
bone
marrowderiv
mast
cell
bmmc
ml
mix
nmoll
sirna
iscov
modifi
dulbecco
medium
place
electropor
chamber
incub
minut
room
temperatur
condit
electropor
v
mf
high
v
fast
charg
minut
recoveri
room
temperatur
cell
return
normal
growth
condit
passiv
sensit
stimul
begun
hour
transfect
bone
marrowderiv
mast
cell
passiv
sensit
ngml
antiova
ige
antibodi
overnight
wash
twice
prewarm
complet
medium
cell
challeng
ova
mgml
minut
wash
complet
media
incub
mrna
analysi
portion
bmmc
harvest
centrifug
minut
hour
ova
addit
remain
bmmc
incub
hour
harvest
media
elisa
assay
valu
measur
express
mean
sem
except
sirna
function
assay
use
luciferasereport
fusion
data
report
mean
sd
describ
data
compar
use
test
assum
unequ
varianc
p
valu
consid
statist
signific
sirna
activ
test
vitro
use
cellbas
dualluciferas
report
assay
describ
text
sirna
test
triplic
ratio
renilla
firefli
luciferas
activ
normal
observ
report
plasmid
transfect
control
sirna
stabil
motif
sirna
use
studi
incorpor
chemic
modif
motif
shown
fig
serv
stabil
sirna
nucleas
evad
dsrnainduc
immun
respons
motif
replac
moieti
sirna
stabil
exonucleas
digest
addit
invert
abas
residu
end
sirna
sens
passeng
strand
pattern
modif
close
relat
previous
describ
morrissey
et
al
differ
motif
fig
lack
termin
phosphorothio
linkag
antisens
strand
place
unmodifi
nucleotid
antisens
strand
regardless
sequenc
versu
unmodifi
purin
nucleotid
modifi
pyrimidin
nucleotid
posit
previou
work
sirna
sequenc
synthes
pattern
modif
differ
describ
morrissey
et
al
posit
depend
sequenc
vitro
sirna
screen
use
either
system
modif
yield
signific
number
activ
sirna
chemic
modifi
sirna
screen
activ
use
cellbas
dualluciferas
report
assay
assay
candid
sirna
cotransfect
hela
cell
plasmid
code
renilla
firefli
luciferas
gene
target
insert
renilla
luciferas
gene
rna
interfer
activ
direct
target
sequenc
result
reduct
renilla
luciferas
activ
rel
firefli
luciferas
serv
control
transfect
effici
seri
sirna
design
synthes
modif
motif
shown
fig
sirna
design
target
rat
sirna
target
sequenc
found
mous
rat
preliminari
screen
activ
sirna
nmoll
screen
rat
report
ten
sirna
test
includ
site
target
mous
rat
elicit
reduct
target
report
activ
potenc
activ
sirna
target
mous
rat
subsequ
assess
doserespons
curv
use
amount
rang
pmoll
result
shown
fig
b
demonstr
chemic
modifi
sirna
inhibitori
concentr
ic
nmoll
site
sirna
show
effect
dosedepend
reduct
target
report
activ
chosen
studi
addit
experi
conduct
bone
marrowderiv
mast
cell
demonstr
activ
sirna
identifi
reporterbas
assay
activ
cell
deriv
balbc
mice
use
model
allergeninduc
ahr
data
shown
fig
demonstr
treatment
sirna
reduc
level
mrna
fig
protein
fig
b
form
activ
antiova
ige
ova
express
rel
unchang
respons
sirna
treatment
control
sirna
target
sequenc
hepat
b
viru
littl
discern
effect
result
demonstr
select
sirna
sequenc
elicit
sequencespecif
effect
primari
cell
balbc
mice
suggest
sirna
may
also
function
vivo
site
sirna
describ
formul
administ
sensit
mice
challeng
use
protocol
outlin
fig
mice
sensit
day
intraperiton
inject
ova
subsequ
challeng
via
airway
nebul
ova
day
mice
inject
intraven
via
tail
vein
control
sirna
hour
first
nebul
ova
challeng
day
hour
challeng
day
rl
measur
hour
last
ova
nebul
sirna
formul
linear
polyethylenimin
formul
report
facilit
effici
deliveri
oligonucleotid
lung
previous
use
deliv
sirna
studi
demonstr
sirnabas
restrict
influenza
replic
data
fig
b
demonstr
treatment
sirna
significantli
reduc
rl
p
higher
dose
mch
assay
hour
last
airway
challeng
control
sirna
chemic
stabil
motif
target
green
fluoresc
protein
gfp
effect
rl
suggest
reduct
rl
sequencespecif
effect
may
relat
target
reduct
signific
shift
p
airway
respons
induc
sirna
also
illustr
calcul
pc
valu
condit
valu
sensit
challeng
anim
treat
sirna
mgml
mch
wherea
valu
sensit
challeng
anim
sensit
challeng
anim
treat
control
sirna
respect
immedi
ahr
measur
perform
lung
lavag
via
tracheal
tube
collect
sampl
cell
count
lung
cytokin
profil
elisa
assay
total
cell
count
number
unchang
sensit
challeng
mice
compar
mice
treat
sirna
also
differenti
cell
count
perform
cell
stain
show
statist
signific
differ
sirna
treatment
compar
sensit
challeng
mice
data
shown
addit
determin
level
level
sever
h
h
cytokin
measur
also
found
show
statist
signific
differ
sirnatr
sirnauntr
sensit
challeng
mice
least
singl
time
point
examin
data
shown
lung
histochemistri
also
perform
shown
fig
substanti
chang
lung
inflamm
stain
chang
goblet
cell
metaplasia
perform
pa
stain
observ
singl
time
point
rna
interfer
power
new
tool
use
explor
contribut
specif
gene
biolog
process
diseas
state
current
studi
demonstr
util
synthet
sirna
well
character
mous
model
allergeninduc
ahr
proofofconcept
studi
chose
target
well
character
mediat
involv
develop
ahr
previou
studi
demonstr
neutral
challeng
phase
sensit
challeng
protocol
reduc
ahr
neutral
genet
delet
also
affect
ahr
murin
model
establish
allerg
airway
diseas
current
studi
use
chemic
modifi
sirna
screen
potenc
cellbas
report
gene
assay
activ
bmmc
chemic
modif
seri
sirna
use
stabil
compound
nucleas
extend
durat
effect
elimin
dsrnainduc
inflammatori
respons
duplex
signific
effect
mrna
protein
level
igeantigenstimul
mast
cell
identifi
sequenc
specif
appar
fact
sirna
effect
mrna
fig
site
sirna
identifi
character
vitro
elicit
signific
reduct
mchinduc
lung
resist
allergen
challeng
sensit
mice
sequenc
depend
effect
demonstr
control
sirna
effect
lung
resist
control
sirna
carri
pattern
chemic
modif
sirna
effect
reduc
level
gfp
target
vitro
best
knowledg
first
demonstr
synthet
sirna
effect
vivo
model
allergeninduc
ahr
one
first
studi
show
sirna
activ
nonvir
respiratori
model
reduc
lung
resist
observ
mice
treat
intraven
inject
contain
mg
sirna
formul
polyethylenimin
polyethylenimin
formul
shown
facilit
deliveri
oligonucleotid
lung
previous
use
studi
demonstr
abil
sirna
restrict
influenza
viru
replic
mice
dose
correspond
approxim
mgkg
rel
low
compar
dose
use
studi
demonstr
sirna
efficaci
vivo
nevertheless
may
possibl
observ
effect
vivo
use
lower
dose
deliv
directli
lung
previou
studi
suggest
chemic
synthes
sirna
reduc
viral
replic
intranas
deliveri
mice
recent
work
shown
sirna
formul
lipid
nanoparticl
show
extens
lung
exposur
halflif
hour
broadli
distribut
mous
lung
intratrach
instil
although
sirna
treatment
lead
reduct
lung
resist
vivo
signific
question
address
futur
studi
primari
among
identif
site
time
sirna
action
associ
reduct
mrna
protein
level
although
sequenc
specif
sirna
establish
vitro
sirna
effect
lung
resist
clearli
sequencedepend
reduct
observ
bal
immedi
lung
function
studi
may
reflect
local
reduct
potenti
close
vicin
airway
smooth
muscl
recent
propos
respond
directli
also
essenti
contributor
develop
goblet
cell
metaplasia
mucu
hyperproduct
administr
sirna
affect
paramet
ahr
goblet
cell
metaplasia
dissoci
also
possibl
amount
requir
goblet
cell
metaplasia
lower
requir
develop
ahr
altern
may
temporari
reduct
critic
ahr
later
mask
influx
inflammatori
cell
airway
also
sourc
number
infiltr
inflammatori
cell
may
secondari
respons
dissoci
develop
ahr
respons
proceed
unimped
face
sirna
treatment
goal
studi
determin
feasibl
interf
allergeninduc
ahr
use
sirna
target
critic
mediat
lung
allerg
respons
clearli
one
sever
critic
mediat
ahr
widespread
effect
may
observ
target
singl
mediat
data
support
notion
sirnamedi
reduct
alter
cours
develop
alter
airway
function
although
work
need
determin
cell
target
sirna
demonstr
sequencedepend
reduct
ahr
model
develop
better
deliveri
perhap
distribut
ie
lung
sirna
treatment
may
promis
new
therapeut
approach
treatment
allergeninduc
airway
dysfunct
thank
current
former
member
gelfand
laboratori
sirna
therapeut
mani
help
convers
grate
acknowledg
diana
nabighian
help
prepar
manuscript
clinic
implic
use
sirna
target
novel
approach
reduc
alter
airway
function
allergen
exposur
could
provid
basi
new
asthma
treatment
